BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases CAMBRIDGE, MA USA and COLUMBIA, MD, March 25, 2024 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer...

BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months Berlin, Germany and Cambridge, MA USA,, March 06, 2024 (GLOBE NEWSWIRE) -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated...